An observational study in Choroidal Melanoma, Indeterminate Lesions and Uveal Melanoma, sponsored by Aura Biosciences. Active, not recruiting at 1 site in Australia. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Aura Biosciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Uveal Melanoma with a site in Australia — 8 open to participants now, 15 under way, 5 of them phase 3. Uveal Melanoma · Australia.
Among the 22 studies in Uveal Melanoma with a site in Australia, this one is one of 4 that started in 2025, is one of 2 observational ones, reaches primary completion later than 10 of the 14 other live ones, and was the 21st registered.
281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.
Browse Uveal Melanoma studies →8 of the 22 studies in Uveal Melanoma with a site in Australia are open now. Recruiting first, the newest first:
IDEAYA Biosciences · Sites in Australia, United States, Canada and 3 more countries
Ages 18+
St Vincent's Hospital, Sydney · Sites in Australia
Ages 18+
IDEAYA Biosciences · Sites in Australia, United States, Austria and 18 more countries
Ages 18+
St Vincent's Hospital, Sydney · Sites in Australia
Ages 18+
Iovance Biotherapeutics, Inc. · Sites in Australia, United States
Ages 18–70
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 10 · Phase 3 5
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 100 across 37 observational studies indexed under Uveal Melanoma.
Median enrollment 108 across the 20 interventional studies, 69 across the 2 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 10 most frequent:
Aura Biosciences is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Aura Biosciences has 7 studies filed under Uveal Melanoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Uveal Melanoma with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT03947385IDEAYA BiosciencesStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | 2027-01-29 |
| NCT04588662Columbia UniversityA Prospective Natural History Study in Uveal Melanoma | 2027-03 |
| NCT05907954IDEAYA Biosciences(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies in Uveal Melanoma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess subject-centric evidence of QoL outcomes in a subset of subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
The AU-011-404 study complements the AU-011-301 clinical trial and aims to identify the broader impact of bel-sar treatment on subjects' daily lives and overall well-being through the collection of PROs. This noninterventional PRO study will provide valuable insights of treatment impact by capturing subject perspective on aspects including symptom management, functional status, and overall health-related quality of life (HRQOL).
The sites will direct interested participants to the study via a unique URL. Upon accessing the URL, participants will be asked to review/sign an informed consent document (ICD). Alternatively, subjects may review and sign a paper version of the informed consent document. Eligible participants will then be asked to answer custom survey questions followed by the EORTC QLQ-C30 and the EORTC QLQ-OPT30 questionnaires at required visits for up to 24 months.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Participating in Aura's Phase 3 CoMpass trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observational
Other: Non-interventional, digital, patient-reported, study
Surveys will be collected at the following CoMpass trial visits. Scheduled visits: Visit 2 Visit 8 Visit 19 Visit 20 Visit 22 Visit 25 Visit 26 Visit 27 Visit 28 Visit 29 And any SOC (Standard of care) Visit
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Core Questionnaire (EORTC )QLQ-C30 scores at weeks 65 and 104.
Change from baseline in EORTC QLQ-C30 scores at weeks 65 and 104 assesses the impact of disease and treatment on the quality of life of patients with cancer. For the minimum and maximum values: All of the scales and single-item measures range in score from 0 to 100. For whether higher scores mean a better or worse outcome: A high-scale score represents a higher response level. Hence high scores for a functional scale represent a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems (A positive change from baseline in functional scales and global health status indicates improvement, while a negative change in symptom scales indicates symptom improvement).
Time frame: 24 months
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Group Questionnaire, Ophthalmic Module (EORTC) QLQ-OPT30 scores at weeks 65 and 104.
Change from baseline in EORTC QLQ-OPT30 scores at weeks 65 and 104 assesses the impact of disease and treatment on the quality of life of patients with ophthalmic cancer specifically. For whether higher scores mean a better or worse outcome: A high-scale score represents a higher response level. Hence high scores for a functional scale represent a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems (A positive change from baseline in functional scales and global health status indicates improvement, while a negative change in symptom scales indicates symptom improvement).
Time frame: 24 months
Plan to share: No
Started Nov 2025 (actual). Primary completion is estimated for Aug 2028, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aura Biosciences